Lincoln Pharma
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
May 28 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
LINCOLN PHARMACEUTICALS - RECOMMENDS DIVIDEND OF 1.80 RUPEE PER SHARE FOR FY2026
LINCOLN PHARMACEUTICALS MARCH-QUARTER CONSOL NET PROFIT 116.3 MILLION RUPEES
LINCOLN PHARMACEUTICALS MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.87 BILLION RUPEES
Source text: ID:nBSE4ZhPFc
Further company coverage: LINP.NS
(([email protected];))
May 28 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
LINCOLN PHARMACEUTICALS - RECOMMENDS DIVIDEND OF 1.80 RUPEE PER SHARE FOR FY2026
LINCOLN PHARMACEUTICALS MARCH-QUARTER CONSOL NET PROFIT 116.3 MILLION RUPEES
LINCOLN PHARMACEUTICALS MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.87 BILLION RUPEES
Source text: ID:nBSE4ZhPFc
Further company coverage: LINP.NS
(([email protected];))
Feb 12 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
LINCOLN PHARMACEUTICALS LTD - DEC-QUARTER CONSOL NET PROFIT 286 MILLION RUPEES
LINCOLN PHARMACEUTICALS LTD - DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 1.66 BILLION RUPEES
Source text: ID:nBSE2sB8FN
Further company coverage: LINP.NS
(([email protected];))
Feb 12 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
LINCOLN PHARMACEUTICALS LTD - DEC-QUARTER CONSOL NET PROFIT 286 MILLION RUPEES
LINCOLN PHARMACEUTICALS LTD - DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 1.66 BILLION RUPEES
Source text: ID:nBSE2sB8FN
Further company coverage: LINP.NS
(([email protected];))
Aug 7 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
JUNE QUARTER CONSOL NET PROFIT 276.8 MILLION RUPEES
JUNE QUARTER CONSOL REVENUE FROM OPERATIONS 1.54 BILLION RUPEES
Source text: [ID:]
Further company coverage: LINP.NS
(([email protected];))
Aug 7 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
JUNE QUARTER CONSOL NET PROFIT 276.8 MILLION RUPEES
JUNE QUARTER CONSOL REVENUE FROM OPERATIONS 1.54 BILLION RUPEES
Source text: [ID:]
Further company coverage: LINP.NS
(([email protected];))
July 2 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
COMPLETES TRIAL RUN OF NEW MANUFACTURING FACILITY
FACILITY EXPECTED TO COMMENCE COMMERCIAL PRODUCTION OF APIS IN 1-2 YEARS
Source text: ID:nBSEbfl6y1
Further company coverage: LINP.NS
(([email protected];;))
July 2 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
COMPLETES TRIAL RUN OF NEW MANUFACTURING FACILITY
FACILITY EXPECTED TO COMMENCE COMMERCIAL PRODUCTION OF APIS IN 1-2 YEARS
Source text: ID:nBSEbfl6y1
Further company coverage: LINP.NS
(([email protected];;))
** Shares of Lincoln Pharmaceuticals LINP.NS fall 3.8% to 639.5 rupees, set to log losses for fifth straight session
** Co's Q3 consol profit fell 25.9% to 207.7 mln rupees ($2.4 mln) as expenses rose while revenue remained nearly flat y/y
** More than 437,000 shares traded, 7.8x its 30-day moving avg, most in a session in over two months
** LINP rose 29.3% in 2024
($1 = 86.8900 Indian rupees)
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected]; +91 8697274436;))
** Shares of Lincoln Pharmaceuticals LINP.NS fall 3.8% to 639.5 rupees, set to log losses for fifth straight session
** Co's Q3 consol profit fell 25.9% to 207.7 mln rupees ($2.4 mln) as expenses rose while revenue remained nearly flat y/y
** More than 437,000 shares traded, 7.8x its 30-day moving avg, most in a session in over two months
** LINP rose 29.3% in 2024
($1 = 86.8900 Indian rupees)
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected]; +91 8697274436;))
Nov 14 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
SEPT-QUARTER CONSOL NET PROFIT 263.3 MILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.61 BILLION RUPEES
Source text: ID:nBSE4BWQDx
Further company coverage: LINP.NS
(([email protected];;))
Nov 14 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
SEPT-QUARTER CONSOL NET PROFIT 263.3 MILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.61 BILLION RUPEES
Source text: ID:nBSE4BWQDx
Further company coverage: LINP.NS
(([email protected];;))
Feb 8 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
LINCOLN PHARMACEUTICALS DEC-QUARTER CONSOL NET PROFIT 280.4 MILLION RUPEES VERSUS PROFIT 216.1 MILLION RUPEES
LINCOLN PHARMACEUTICALS DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 1.46 BILLION RUPEES VERSUS 1.34 BILLION RUPEES
Source text for Eikon: ID:nBSE9j6pPR
Further company coverage: LINP.NS
(([email protected];))
Feb 8 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
LINCOLN PHARMACEUTICALS DEC-QUARTER CONSOL NET PROFIT 280.4 MILLION RUPEES VERSUS PROFIT 216.1 MILLION RUPEES
LINCOLN PHARMACEUTICALS DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 1.46 BILLION RUPEES VERSUS 1.34 BILLION RUPEES
Source text for Eikon: ID:nBSE9j6pPR
Further company coverage: LINP.NS
(([email protected];))
** Shares of Lincoln Pharmaceuticals LINP.NS rise as much as 8.5% to 537 rupees, steepest gain since Aug. 24
** Pharma co's Sept-quarter consol net profit jumps 16.6% Y/Y; rev from ops surges 10.9%
** More than 447,000 shares traded by 12.51 p.m. IST, 8.9x its 30-day avg
** Stock last up 7.2%, extending YTD gains to 49.2% against an 18% YTD growth in benchmark Nifty Pharma Index .NIPHARM
(Reporting by Aleef Jahan in Bengaluru)
** Shares of Lincoln Pharmaceuticals LINP.NS rise as much as 8.5% to 537 rupees, steepest gain since Aug. 24
** Pharma co's Sept-quarter consol net profit jumps 16.6% Y/Y; rev from ops surges 10.9%
** More than 447,000 shares traded by 12.51 p.m. IST, 8.9x its 30-day avg
** Stock last up 7.2%, extending YTD gains to 49.2% against an 18% YTD growth in benchmark Nifty Pharma Index .NIPHARM
(Reporting by Aleef Jahan in Bengaluru)
Aug 10 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
JUNE-QUARTER CONSOL NET PROFIT 190.1 MILLION RUPEES VERSUS 150.1 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.36 BILLION RUPEES VERSUS 1.23 BILLION RUPEES
Source text for Eikon: ID:nBSE1nXp21
Further company coverage: LINP.NS
(([email protected];))
Aug 10 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
JUNE-QUARTER CONSOL NET PROFIT 190.1 MILLION RUPEES VERSUS 150.1 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.36 BILLION RUPEES VERSUS 1.23 BILLION RUPEES
Source text for Eikon: ID:nBSE1nXp21
Further company coverage: LINP.NS
(([email protected];))
May 25 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
DIVIDEND 1.5 RUPEES PER SHARE
MARCH-QUARTER CONSOL NET PROFIT 125.6 MILLION RUPEES VERSUS 110.2 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.12 BILLION RUPEES VERSUS 1.03 BILLION RUPEES
Source text for Eikon: ID:nBSE8Sy3sY
Further company coverage: LINP.NS
(([email protected];))
May 25 (Reuters) - Lincoln Pharmaceuticals Ltd LINP.NS:
DIVIDEND 1.5 RUPEES PER SHARE
MARCH-QUARTER CONSOL NET PROFIT 125.6 MILLION RUPEES VERSUS 110.2 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.12 BILLION RUPEES VERSUS 1.03 BILLION RUPEES
Source text for Eikon: ID:nBSE8Sy3sY
Further company coverage: LINP.NS
(([email protected];))
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Lincoln Pharma do?
Lincoln Pharmaceuticals Ltd specializes in producing and promoting cost-effective therapeutic products such as Tablets, Capsules, Injectables, Syrups, and Ointments.
Who are the competitors of Lincoln Pharma?
Lincoln Pharma major competitors are Wanbury, Syncom Formulations, Bharat Parenterals, Jagsonpal Pharma, Fredun Pharma, Anuh Pharma, Zim Laboratories. Market Cap of Lincoln Pharma is ₹1,207 Crs. While the median market cap of its peers are ₹1,174 Crs.
Is Lincoln Pharma financially stable compared to its competitors?
Lincoln Pharma seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Lincoln Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Lincoln Pharma latest dividend payout ratio is 4.38% and 3yr average dividend payout ratio is 4.12%
How has Lincoln Pharma allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Lincoln Pharma balance sheet?
Balance sheet of Lincoln Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Lincoln Pharma improving?
The profit is oscillating. The profit of Lincoln Pharma is ₹87.89 Crs for TTM, ₹82.35 Crs for Mar 2025 and ₹93.3 Crs for Mar 2024.
Is the debt of Lincoln Pharma increasing or decreasing?
Yes, The net debt of Lincoln Pharma is increasing. Latest net debt of Lincoln Pharma is -₹28.23 Crs as of Mar-26. This is greater than Mar-25 when it was -₹44.36 Crs.
Is Lincoln Pharma stock expensive?
Yes, Lincoln Pharma is expensive. Latest PE of Lincoln Pharma is 13.74, while 3 year average PE is 12.36. Also latest EV/EBITDA of Lincoln Pharma is 12.07 while 3yr average is 10.4.
Has the share price of Lincoln Pharma grown faster than its competition?
Lincoln Pharma has given lower returns compared to its competitors. Lincoln Pharma has grown at ~15.1% over the last 8yrs while peers have grown at a median rate of 26.73%
Is the promoter bullish about Lincoln Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Lincoln Pharma is 49.78% and last quarter promoter holding is 49.78%.
Are mutual funds buying/selling Lincoln Pharma?
There is Insufficient data to gauge this.